Alkem Labs Slashes Diabetes Drug Cost by 80% with New Drug Launch
In a groundbreaking move, Alkem Laboratories, a leading pharmaceutical company in India, has launched Empanorm, a generic version of empagliflozin, a widely prescribed medication for the treatment of diabetes, heart failure, and kidney disease. What sets Empanorm apart is its significantly lower price point, which is a whopping 80% lower than the existing prices of similar medications in the market.
The launch of Empanorm is a significant development in the Indian pharmaceutical industry, as it aims to improve accessibility and affordability for patients across the country. The new drug is expected to have a profound impact on the lives of millions of Indians who suffer from diabetes, heart failure, and kidney disease.
Empagliflozin is a widely prescribed medication for the treatment of type 2 diabetes, heart failure, and kidney disease. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which works by blocking the reabsorption of glucose in the kidneys, thereby reducing blood sugar levels. The medication has been widely used worldwide due to its effectiveness in managing these chronic conditions.
The launch of Empanorm is a result of Alkem Laboratories’ commitment to innovation and patient-centric approach. The company has developed a smaller tablet size, anti-counterfeit security, and multilingual patient education to ensure that the medication is accessible and usable for patients across India.
Smaller Tablet Size
One of the key features of Empanorm is its smaller tablet size, which makes it easier for patients to swallow and manage. The smaller tablet size is particularly beneficial for pediatric patients, elderly patients, and patients with dysphagia, who often struggle with larger tablet sizes.
Anti-Counterfeit Security
Alkem Laboratories has also incorporated anti-counterfeit security features in Empanorm to prevent counterfeit products from entering the market. The company has implemented a unique authentication system that ensures the authenticity of its products and protects patients from fake or substandard medications.
Multilingual Patient Education
The company has also developed patient education materials in multiple languages, including Hindi, Marathi, and Bengali, to ensure that patients can understand the medication’s instructions and benefits. This is particularly important for patients who may not have access to healthcare professionals or may not speak English.
Impact on Patients and Healthcare System
The launch of Empanorm is expected to have a significant impact on patients and the healthcare system in India. With a lower price point, the medication is expected to increase accessibility and affordability for patients, particularly in rural and semi-urban areas where healthcare infrastructure is limited.
The medication is also expected to reduce the burden on the healthcare system, as it can be used to treat multiple chronic conditions simultaneously. This can lead to better health outcomes, reduced hospitalization rates, and lower healthcare costs in the long run.
Industry Reaction
The industry has welcomed the launch of Empanorm, with many players in the pharmaceutical sector expressing their support for the initiative. “Alkem Laboratories’ launch of Empanorm is a significant step towards improving accessibility and affordability for patients in India,” said a spokesperson for the Indian Pharmaceutical Alliance. “We hope that this initiative will inspire other companies to follow suit and work towards making quality healthcare more accessible to all.”
Conclusion
The launch of Empanorm is a significant development in the Indian pharmaceutical industry, as it aims to improve accessibility and affordability for patients across the country. With a smaller tablet size, anti-counterfeit security, and multilingual patient education, Empanorm is expected to have a profound impact on the lives of millions of Indians who suffer from diabetes, heart failure, and kidney disease. As the company continues to work towards making quality healthcare more accessible to all, the industry is likely to see a shift towards more patient-centric and affordable medications in the future.
News Source:
https://www.healthcareradius.in/features/pharma/alkem-labs-diabetes-drug
